We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
| Form | Report Date | Filing Date | Description |
|---|---|---|---|
| 6-K | 2026-10-05 | 2026-10-05 | ASTRAZENECA COMPLETES EQUITY INVESTMENT IN SUMMIT |
| 6-K | 2026-10-02 | 2026-10-02 | AZ & DS COLLABORATION WITH SUMMIT FOR DATROWAY |
| 6-K | 2026-10-01 | 2026-10-01 | TOTAL VOTING RIGHTS |
| 6-K | 2026-10-01 | 2026-10-01 | ADMISSION OF FURTHER SECURITIES TO TRADING |
| 6-K | 2026-09-29 | 2026-09-29 | ASTRAZENECA ANNOUNCES EQUITY INVESTMENT IN SUMMIT |
| 6-K | 2026-09-23 | 2026-09-23 | TRIXEO APPROVED IN EU FOR ASTHMA |
| 6-K | 2026-09-21 | 2026-09-21 | ENHERTU RECOMMENDED FOR APPROVAL IN EU IN EARLY BC |
| 6-K | 2026-09-21 | 2026-09-21 | KLYGEFA RECOMMENDED FOR EU APPROVAL BY CHMP |
| 6-K | 2026-09-18 | 2026-09-18 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-09-15 | 2026-09-15 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-09-15 | 2026-09-15 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-09-14 | 2026-09-14 | UPDATE ON SERENA-4 PHASE III TRIAL |
| 6-K | 2026-09-08 | 2026-09-08 | ETCAMAH APPROVED IN THE US FOR HR+ BREAST CANCER |
| 6-K | 2026-09-08 | 2026-09-08 | IMFINZI+IMDELLTRA IMPROVED OS IN SMALL CELL LUNG |
| 6-K | 2026-09-01 | 2026-09-01 | TAGRISSO + ORPATHYS IMPROVED PFS IN 1L EGFRM LUNG |
| 6-K | 2026-09-01 | 2026-09-01 | ASTRAZENECA COMPLETES AGREEMENT FOR ZEGFROVY |
| 6-K | 2026-09-01 | 2026-09-01 | DIRECTORATE CHANGE |
| 6-K | 2026-09-01 | 2026-09-01 | ENHERTU APPROVED IN EU FOR 1L HER2-POSITIVE MBC |
| 6-K | 2026-09-01 | 2026-09-01 | ADMISSION TO TRADING - EUR2.55 BILLION BOND OFFERING |
| 6-K | 2026-09-01 | 2026-09-01 | TOTAL VOTING RIGHTS |
| 6-K | 2026-09-01 | 2026-09-01 | ADMISSION OF FURTHER SECURITIES TO TRADING |
| 6-K | 2026-08-27 | 2026-08-27 | TEZSPIRE CROSSING TRIAL MET PRIMARY ENDPOINTS |
| 6-K | 2026-08-25 | 2026-08-25 | ASTRAZENECA PRICES A EUR2.55 BILLION BOND OFFERING |
| 6-K | 2026-08-19 | 2026-08-19 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-08-17 | 2026-08-17 | TAGRISSO+ORPATHYS IMPROVED PFS & OS IN EGFRM LUNG |
| 6-K | 2026-08-17 | 2026-08-17 | UPDATE ON EVOLVE-LUNG02 PHASE III TRIAL |
| 6-K | 2026-08-17 | 2026-08-17 | ENHERTU IMPROVED PFS IN 1L HER2M LUNG CANCER |
| 6-K | 2026-08-03 | 2026-08-03 | TOTAL VOTING RIGHTS |
| 6-K | 2026-08-03 | 2026-08-03 | ADMISSION OF FURTHER SECURITIES TO TRADING |
| 6-K | 2026-07-31 | 2026-07-31 | DATROWAY APPROVED IN EU FOR TNBC |
| 6-K | 2026-07-27 | 2026-07-27 | SONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERS |
| 6-K | 2026-06-30 | 2026-07-27 | FORM 6-K |
| 6-K | 2026-07-27 | 2026-07-27 | UPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMA |
| 6-K | 2026-07-23 | 2026-07-23 | ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER |
| 6-K | 2026-07-14 | 2026-07-14 | ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR |
| 6-K | 2026-07-09 | 2026-07-09 | UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL |
| 6-K | 2026-07-01 | 2026-07-01 | ADMISSION OF FURTHER SECURITIES TO TRADING |
| 6-K | 2026-07-01 | 2026-07-01 | TOTAL VOTING RIGHTS |
| 6-K | 2026-06-29 | 2026-06-29 | ENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURS |
| 6-K | 2026-06-29 | 2026-06-29 | DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC |
| 6-K | 2026-06-15 | 2026-06-15 | TRUQAP APPROVED IN US FOR PROSTATE CANCER |
| 6-K | 2026-06-01 | 2026-06-01 | TOTAL VOTING RIGHTS |
| 6-K | 2026-06-01 | 2026-06-01 | ADMISSION OF FURTHER SECURITIES TO TRADING |
| 6-K | 2026-05-29 | 2026-05-29 | IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER |
| 6-K | 2026-05-27 | 2026-05-27 | US FDA DECISION DATE ON CAMIZESTRANT EXTENDED |
| 6-K | 2026-05-26 | 2026-05-26 | DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC |
| 6-K | 2026-05-26 | 2026-05-26 | ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS |
| 6-K | 2026-05-26 | 2026-05-26 | CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU |
| 6-K | 2026-05-18 | 2026-05-18 | BAXFENDY APPROVED IN THE US FOR HYPERTENSION |
| 6-K | 2026-05-18 | 2026-05-18 | ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS |
| 6-K | 2026-05-18 | 2026-05-18 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-05-14 | 2026-05-14 | IMFINZI + EV IMPROVES EFS & OS IN BLADDER CANCER |
| 6-K | 2026-05-01 | 2026-05-01 | FDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCER |
| 6-K | 2026-05-01 | 2026-05-01 | FDA ODAC RECOMMENDS TRUQAP IN PROSTATE CANCER |
| 6-K | 2026-05-01 | 2026-05-01 | TOTAL VOTING RIGHTS AND ADMISSION OF SHARES |
| 6-K | 2026-04-29 | 2026-04-29 | 1ST QUARTER RESULTS |
| 6-K | 2026-04-28 | 2026-04-28 | BREZTRI APPROVED IN THE US FOR ASTHMA |
| 6-K | 2026-04-27 | 2026-04-27 | SAPHNELO SELF-ADMINISTRATION APPROVED IN THE US |
| 6-K | 2026-04-23 | 2026-04-23 | DIRECTORATE CHANGE |
| 6-K | 2026-04-21 | 2026-04-21 | I CAN PHIII INTERIM ANALYSIS MET PRIMARY ENDPOINT |
| 6-K | 2026-04-20 | 2026-04-20 | THIRD TOZORAKIMAB POSITIVE PHASE III IN COPD |
| 6-K | 2026-04-09 | 2026-04-09 | RESULT OF AGM |
| 6-K | 2026-04-02 | 2026-04-02 | IMFINZI+IMJUDO IMPROVES PFS IN EARLY LIVER CANCER |
| 6-K | 2026-04-01 | 2026-04-01 | TOTAL VOTING RIGHTS AND ADMISSION OF SHARES |
| 6-K | 2026-03-31 | 2026-03-31 | EFZIMFOTASE ALFA PH3 PROGRAM SHOW POSITIVE RESULTS |
| 6-K | 2026-03-27 | 2026-03-27 | TOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTS |
| 6-K | 2026-03-20 | 2026-03-20 | NOTIFICATION OF ADMISSION OF SHARES |
| 6-K | 2026-03-16 | 2026-03-16 | IMFINZI APPROVED IN EU FOR EARLY GASTRIC CANCER |
| 6-K | 2026-03-10 | 2026-03-10 | FORM 6-K |
| 6-K | 2026-03-10 | 2026-03-10 | NOTICE OF AGM |
| 6-K | 2026-03-06 | 2026-03-06 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-03-06 | 2026-03-06 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-03-06 | 2026-03-06 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-03-02 | 2026-03-02 | TOTAL VOTING RIGHTS |
| 6-K | 2026-03-02 | 2026-03-02 | FORM 6-K |
| 6-K | 2026-02-26 | 2026-02-26 | ASTRAZENECA PRICES A $2BN BOND OFFERING |
| 6-K | 2026-02-25 | 2026-02-25 | FILING OF FORM 20-F WITH SEC |
| 6-K | 2026-02-24 | 2026-02-24 | DIRECTORATE CHANGE |
| 6-K | 2026-02-24 | 2026-02-24 | ANNUAL FINANCIAL REPORT |
| 6-K | 2026-02-24 | 2026-02-24 | FORM 6-K |
| 20-F | 2025-12-31 | 2026-02-24 | 20-F |
| 6-K | 2026-02-20 | 2026-02-20 | FIXED-DURATION CALQUENCE COMBO APPROVED IN US |
| 6-K | 2026-02-10 | 2026-02-10 | FINAL RESULTS |
| 6-K | 2026-02-03 | 2026-02-03 | UPDATE ON SAPHNELO SUBCUTANEOUS ADMINISTRATION |
| 6-K | 2026-02-02 | 2026-02-02 | ASTRAZENECA BEGINS TRADING ON NYSE |
| 6-K | 2026-02-02 | 2026-02-02 | TOTAL VOTING RIGHTS |
| 6-K | 2026-02-02 | 2026-02-02 | IMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCER |
| 6-K | 2026-01-30 | 2026-01-30 | ASTRAZENECA AGREES OBESITY AND T2D DEAL WITH CSPC |
| 6-K | 2026-01-29 | 2026-01-29 | ASTRAZENECA INVESTS $15BN IN CHINA THROUGH 2030 |
| 6-K | 2026-01-20 | 2026-01-20 | ASTRAZENECA TO COMPLETE DIRECT LISTING ON NYSE |
| 6-K | 2026-01-08 | 2026-01-08 | AZN NEW HEAD OF INVESTOR RELATIONS JORIS SILON |
| 6-K | 2026-01-02 | 2026-01-02 | TOTAL VOTING RIGHTS |
| 6-K | 2025-12-22 | 2025-12-22 | ENHERTU GRANTED BTD FOR POST-NEOADJUVANT EARLY BC |
| 6-K | 2025-12-22 | 2025-12-22 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-12-22 | 2025-12-22 | UPDATE ON LATIFY PHASE III TRIAL OF CERALASERTIB |
| 6-K | 2025-12-19 | 2025-12-19 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-12-16 | 2025-12-16 | SUBCUTANEOUS SAPHNELO APPROVED IN EU |
| 6-K | 2025-12-16 | 2025-12-16 | ENHERTU APPROVED IN US FOR 1L HER2+ METASTATIC BC |
| 6-K | 2025-12-04 | 2025-12-04 | HOLDING(S) IN COMPANY |
| 6-K | 2025-12-01 | 2025-12-01 | TOTAL VOTING RIGHTS |
| 6-K | 2025-12-01 | 2025-12-01 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2025-11-26 | 2025-11-26 | IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCER |
| 6-K | 2025-11-24 | 2025-11-24 | ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLAND |
| 6-K | 2025-11-20 | 2025-11-20 | KOSELUGO (SELUMETINIB) APPROVED IN THE US |
| 6-K | 2025-11-17 | 2025-11-17 | HOLDING(S) IN COMPANY |
| 6-K | 2025-11-14 | 2025-11-14 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-11-10 | 2025-11-10 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-11-06 | 2025-11-06 | 9M AND Q3 2025 RESULTS |
| 6-K | 2025-11-03 | 2025-11-03 | RESULT OF GENERAL MEETING |
| 6-K | 2025-11-03 | 2025-11-03 | TOTAL VOTING RIGHTS |
| 6-K | 2025-11-03 | 2025-11-03 | FORM 6-K |
| 6-K | 2025-10-28 | 2025-10-28 | DIRECTOR DECLARATION |
| 6-K | 2025-10-28 | 2025-10-28 | KOSELUGO (SELUMETINIB) APPROVED IN THE EU |
| 6-K | 2025-10-22 | 2025-10-22 | TEZSPIRE APPROVED IN EU FOR CRSWNP |
| 6-K | 2025-10-20 | 2025-10-20 | POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELO |
| 6-K | 2025-10-20 | 2025-10-20 | US FDA APPROVES TEZSPIRE IN CRSWNP |
| 6-K | 2025-10-14 | 2025-10-14 | AGREEMENT WITH US GOVT TO LOWER MEDICINE PRICES |
| 6-K | 2025-10-07 | 2025-10-07 | BAXDROSTAT MET PRIMARY ENDPOINT IN BAX24 PH3 TRIAL |
| 6-K | 2025-10-06 | 2025-10-06 | DATROWAY IMPROVED OS AND PFS IN TROPION-BREAST02 |
| 6-K | 2025-10-01 | 2025-10-01 | TOTAL VOTING RIGHTS |
| 6-K | 2025-09-29 | 2025-09-29 | ENHERTU IMPROVED IDFS IN EARLY BC IN DB-05 |
| 6-K | 2025-09-29 | 2025-09-29 | 6-K |
| 6-K | 2025-09-29 | 2025-09-29 | AZN HARMONISES LISTING STRUCTURE |
| 6-K | 2025-09-25 | 2025-09-25 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-09-22 | 2025-09-22 | TEZSPIRE RECOMMENDED FOR APPROVAL IN EU FOR CRSWNP |
| 6-K | 2025-09-22 | 2025-09-22 | KOSELUGO RECOMMENDED FOR EU APPROVAL |
| 6-K | 2025-09-17 | 2025-09-17 | UPDATE ON RESOLUTE PHASE III TRIAL |
| 6-K | 2025-09-17 | 2025-09-17 | SAPHNELO MET PRIMARY ENDPOINT IN TULIP-SC |
| 6-K | 2025-09-02 | 2025-09-02 | TOTAL VOTING RIGHTS |
| 6-K | 2025-08-28 | 2025-08-28 | HOLDING(S) IN COMPANY |
| 6-K | 2025-08-26 | 2025-08-26 | HOLDING(S) IN COMPANY |
| 6-K | 2025-08-21 | 2025-08-21 | HOLDING(S) IN COMPANY |
| 6-K | 2025-08-18 | 2025-08-18 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-08-15 | 2025-08-15 | HOLDING(S) IN COMPANY |
| 6-K | 2025-08-12 | 2025-08-12 | HOLDING(S) IN COMPANY |
| 6-K | 2025-08-01 | 2025-08-01 | TOTAL VOTING RIGHTS |
| 6-K | 2025-06-30 | 2025-07-29 | FORM 6-K |
| 6-K | 2025-07-24 | 2025-07-24 | GEFURULIMAB NANOBODY MET PHASE III ENDPOINTS |
| 6-K | 2025-07-22 | 2025-07-22 | ASTRAZENECA PLANS TO INVEST $50BN IN THE US |
| 6-K | 2025-07-16 | 2025-07-16 | UPDATE ON ANSELAMIMAB IN AL AMYLOIDOSIS |
| 6-K | 2025-07-14 | 2025-07-14 | BAXDROSTAT MET PRIMARY ENDPT IN BAXHTN PHIII TRIAL |
| 6-K | 2025-07-07 | 2025-07-07 | IMFINZI APPROVED IN THE EU FOR BLADDER CANCER |
| 6-K | 2025-07-01 | 2025-07-01 | TOTAL VOTING RIGHTS |
| 6-K | 2025-06-24 | 2025-06-24 | DATROWAY APPROVED IN US FOR EGFRM LUNG CANCER |
| 6-K | 2025-06-13 | 2025-06-13 | ASTRAZENECA ENTERS INTO COLLABORATION WITH CSPC |
| 6-K | 2025-06-12 | 2025-06-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-06-06 | 2025-06-06 | FIXED-DURATION CALQUENCE APPROVED IN EU FOR 1L CLL |
| 6-K | 2025-06-02 | 2025-06-02 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2025-06-02 | 2025-06-02 | TOTAL VOTING RIGHTS |
| 6-K | 2025-05-27 | 2025-05-27 | IMFINZI RECOMMENDED IN EU FOR BLADDER CANCER |
| 6-K | 2025-05-23 | 2025-05-23 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-05-21 | 2025-05-21 | DIRECTOR DECLARATION |
| 6-K | 2025-05-20 | 2025-05-20 | ACQUISITION OF ESOBIOTEC COMPLETED |
| 6-K | 2025-05-09 | 2025-05-09 | IMFINZI IMPROVED DFS IN EARLY BLADDER CANCER |
| 6-K | 2025-05-07 | 2025-05-07 | ENHERTU IMPROVED PCR IN EARLY-STAGE BREAST CANCER |
| 6-K | 2025-05-06 | 2025-05-06 | CALQUENCE COMBINATION APPROVED IN EU FOR 1L MCL |
| 6-K | 2025-05-02 | 2025-05-02 | BREZTRI MET PRIMARY ENDPOINTS IN PH3 ASTHMA TRIALS |
| 6-K | 2025-05-01 | 2025-05-01 | TOTAL VOTING RIGHTS |
| 6-K | 2025-05-01 | 2025-05-01 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-04-29 | 2025-04-29 | FIXED-DURATION CALQUENCE RECOMMENDED IN EU FOR CLL |
| 6-K | 2025-04-29 | 2025-04-29 | UPDATE ON CAPITELLO-280 PHASE III TRIAL |
| 6-K | 2025-04-29 | 2025-04-29 | 1ST QUARTER RESULTS |
| 6-K | 2025-04-22 | 2025-04-22 | ENHERTU COMBINATION IMPROVED PFS IN 1L HER2+ MBC |
| 6-K | 2025-04-11 | 2025-04-11 | RESULT OF AGM |
| 6-K | 2025-04-04 | 2025-04-04 | ENHERTU APPROVED IN EU IN POST-ET BREAST CANCER |
| 6-K | 2025-04-04 | 2025-04-04 | IMFINZI APPROVED IN EU FOR AEGEAN |
| 6-K | 2025-04-01 | 2025-04-01 | TOTAL VOTING RIGHTS |
| 6-K | 2025-03-31 | 2025-03-31 | IMFINZI APPROVED IN THE US FOR BLADDER CANCER |
| 6-K | 2025-03-31 | 2025-03-31 | CALQUENCE RECOMMENDED FOR EU APPROVAL IN 1L MCL |
| 6-K | 2025-03-21 | 2025-03-21 | AZN INVESTS $2.5BN IN BEIJING R&D & MANUFACTURING |
| 6-K | 2025-03-17 | 2025-03-17 | IMFINZI APPROVED IN EU FOR LIMITED-STAGE SCLC |
| 6-K | 2025-03-17 | 2025-03-17 | ASTRAZENECA TO ACQUIRE ESOBIOTEC |
| 6-K | 2025-03-17 | 2025-03-17 | ENEBOPARATIDE PHASE III TRIAL MET PRIMARY ENDPOINT |
| 6-K | 2025-03-12 | 2025-03-12 | HOLDING(S) IN COMPANY |
| 6-K | 2025-03-07 | 2025-03-07 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-03-07 | 2025-03-07 | FORM 6-K |
| 6-K | 2025-03-07 | 2025-03-07 | IMFINZI IMPROVED EFS IN EARLY-STAGE GASTRIC CANCER |
| 6-K | 2025-03-07 | 2025-03-07 | NOTICE OF AGM |
| 6-K | 2025-03-06 | 2025-03-06 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-03-05 | 2025-03-05 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-03-03 | 2025-03-03 | IMFINZI RECOMMENDED FOR EU APPROVAL FOR AEGEAN |
| 6-K | 2025-03-03 | 2025-03-03 | TOTAL VOTING RIGHTS |
| 6-K | 2025-02-28 | 2025-02-28 | ENHERTU RECOMMENDED IN EU IN POST-ET BREAST CANCER |
| 6-K | 2025-02-26 | 2025-02-26 | CAMIZESTRANT IMPROVED PFS IN 1L HR+ BREAST CANCER |
| 6-K | 2025-02-19 | 2025-02-19 | FILING OF FORM 20-F WITH SEC |
| 6-K | 2025-02-18 | 2025-02-18 | ANNUAL FINANCIAL REPORT |
| 20-F | 2024-12-31 | 2025-02-18 | FORM 20-F |
| 6-K | 2025-02-18 | 2025-02-18 | FORM 6-K |
| 6-K | 2025-02-18 | 2025-02-18 | HOLDING(S) IN COMPANY |
| 6-K | 2025-02-18 | 2025-02-18 | DIRECTORATE CHANGE |
| 6-K | 2025-02-06 | 2025-02-06 | FINAL RESULTS |
| 6-K | 2025-02-03 | 2025-02-03 | TOTAL VOTING RIGHTS |
| 6-K | 2025-02-03 | 2025-02-03 | IMFINZI RECOMMENDED FOR EU APPROVAL FOR LS-SCLC |
| 6-K | 2025-01-28 | 2025-01-28 | ENHERTU APPROVED IN US FOR BREAST CANCER POST ET |
| 6-K | 2025-01-21 | 2025-01-21 | DATO-DXD APPROVED IN US FOR HR+ BREAST CANCER |
| 6-K | 2025-01-17 | 2025-01-17 | CALQUENCE COMBINATION APPROVED IN US FOR 1L MCL |
| 6-K | 2025-01-02 | 2025-01-02 | TOTAL VOTING RIGHTS |
| 6-K | 2024-12-26 | 2024-12-26 | DATO-DXD NSQ NSCLC APPLICATION WITHDRAWN IN EU |
| 6-K | 2024-12-23 | 2024-12-23 | TAGRISSO APPROVED IN EU BASED ON LAURA TRIAL |
| 6-K | 2024-12-16 | 2024-12-16 | DIRECTORATE CHANGE |
| 6-K | 2024-12-05 | 2024-12-05 | IMFINZI APPROVED IN US FOR LIMITED-STAGE SCLC |
| 6-K | 2024-12-04 | 2024-12-04 | ASTRAZENECA APPOINTS ISKRA REIC EVP INTERNATIONAL |
| 6-K | 2024-12-02 | 2024-12-02 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2024-12-02 | 2024-12-02 | TOTAL VOTING RIGHTS |
| 6-K | 2024-11-25 | 2024-11-25 | TRUQAP IMPROVED RPFS IN ADVANCED PROSTATE CANCER |
| 6-K | 2024-11-20 | 2024-11-20 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-11-18 | 2024-11-18 | TAGRISSO RECOMMENDED FOR EU APPROVAL - LAURA |
| 6-K | 2024-11-15 | 2024-11-15 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-11-15 | 2024-11-15 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-11-13 | 2024-11-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-11-12 | 2024-11-12 | 9M AND Q3 2024 RESULTS |
| 6-K | 2024-11-12 | 2024-11-12 | ASTRAZENECA INVESTS $3.5 BILLION IN US |
| 6-K | 2024-11-12 | 2024-11-12 | KOMET PHASE III TRIAL MET PRIMARY ENDPOINT |
| 6-K | 2024-11-12 | 2024-11-12 | DATO-DXD NEW BLA SUBMITTED, NSQ BLA WITHDRAWN |
| 6-K | 2024-11-08 | 2024-11-08 | TEZSPIRE NASAL POLYPS TRIAL MET PRIMARY ENDPOINTS |
| 6-K | 2024-11-01 | 2024-11-01 | TOTAL VOTING RIGHTS |
| 6-K | 2024-10-30 | 2024-10-30 | AZN CHINA PRESIDENT UNDER INVESTIGATION |
| 6-K | 2024-10-21 | 2024-10-21 | FORM 6-K |
| 6-K | 2024-10-07 | 2024-10-07 | ASTRAZENECA LICENSES LIPID LOWERING LP(A) ASSET |
| 6-K | 2024-10-01 | 2024-10-01 | TOTAL VOTING RIGHTS |
| 6-K | 2024-09-26 | 2024-09-26 | TAGRISSO US APPROVAL IN UNRESECTABLE LUNG CANCER |
| 6-K | 2024-09-23 | 2024-09-23 | FINAL OS RESULTS REPORTED FOR TROPION - BREAST01 |
| 6-K | 2024-09-23 | 2024-09-23 | FASENRA RECOMMENDED FOR EU APPROVAL IN EGPA |
| 6-K | 2024-09-20 | 2024-09-20 | FLUMIST APPROVED FOR SELF-ADMINISTRATION IN US |
| 6-K | 2024-09-18 | 2024-09-18 | FASENRA EGPA US FDA APPROVAL |
| 6-K | 2024-09-13 | 2024-09-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-09-02 | 2024-09-03 | TOTAL VOTING RIGHTS |
| 6-K | 2024-08-16 | 2024-08-16 | IMFINZI APPROVED IN US FOR RESECTABLE LUNG CANCER |
| 6-K | 2024-08-01 | 2024-08-01 | TOTAL VOTING RIGHTS |
| 6-K | 2024-07-30 | 2024-07-30 | ASTRAZENECA PRICES A EUR1.4BN BOND OFFERING |
| 6-K | 2024-07-29 | 2024-07-29 | CALQUENCE FIXED-DURATION COMBO IMPROVED 1L CLL PFS |
| 6-K | 2024-07-26 | 2024-07-26 | ODAC REVIEWED IMFINZI IN RESECTABLE LUNG CANCER |
| 6-K | 2024-06-30 | 2024-07-25 | FORM 6K |
| 6-K | 2024-07-15 | 2024-07-15 | ACQUISITION OF AMOLYT PHARMA COMPLETED |
| 6-K | 2024-07-01 | 2024-07-01 | LYNPARZA & IMFINZI POSITIVE CHMP IN ENDOMETRIAL |
| 6-K | 2024-07-01 | 2024-07-01 | TOTAL VOTING RIGHTS |
| 6-K | 2024-06-25 | 2024-06-25 | UPDATE ON IMFINZI ADJUVANT BR.31 TRIAL |
| 6-K | 2024-06-25 | 2024-06-25 | IMFINZI IMPROVED EFS AND OS IN BLADDER CANCER |
| 6-K | 2024-06-18 | 2024-06-18 | UPDATE ON CAPITELLO-290 PHASE III TRIAL |
| 6-K | 2024-06-17 | 2024-06-17 | IMFINZI APPROVED IN THE US FOR ENDOMETRIAL CANCER |
| 6-K | 2024-06-12 | 2024-06-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-06-04 | 2024-06-04 | FORM 6-K |
| 6-K | 2024-06-03 | 2024-06-03 | TOTAL VOTING RIGHTS |
| 6-K | 2024-06-03 | 2024-06-03 | TAGRISSO PLUS CHEMO RECOMMENDED FOR APPROVAL IN EU |
| 6-K | 2024-06-03 | 2024-06-03 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2024-05-28 | 2024-05-28 | DATO-DXD IMPROVED OS IN NONSQUAMOUS LUNG CANCER |
| 6-K | 2024-05-21 | 2024-05-21 | ASTRAZENECA TO DELIVER $80BN REVENUE BY 2030 |
| 6-K | 2024-05-20 | 2024-05-20 | ASTRAZENECA TO MANUFACTURE ADCS IN SINGAPORE |
| 6-K | 2024-05-16 | 2024-05-16 | SUPERNOVA TRIAL MET COVID-19 PREVENTION ENDPOINT |
| 6-K | 2024-05-15 | 2024-05-15 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-05-07 | 2024-05-07 | ASTRAZENECA COMPLETES CELLECTIS EQUITY INVESTMENT |
| 6-K | 2024-05-02 | 2024-05-02 | CALQUENCE COMBINATION IMPROVED PFS IN 1L MCL |
| 6-K | 2024-05-01 | 2024-05-01 | TOTAL VOTING RIGHTS |
| 6-K | 2024-04-29 | 2024-04-29 | TRUQAP RECOMMENDED FOR EU BREAST CANCER APPROVAL |
| 6-K | 2024-04-29 | 2024-04-29 | ENHERTU IMPROVED PFS IN HER2-LOW AND ULTRALOW |
| 6-K | 2024-04-25 | 2024-04-25 | 1ST QUARTER RESULTS |
| 6-K | 2024-04-11 | 2024-04-11 | RESULT OF AGM |
| 6-K | 2024-04-11 | 2024-04-11 | ASTRAZENECA INCREASES 2024 DIVIDEND BY 7% |
| 6-K | 2024-04-08 | 2024-04-08 | ENHERTU APPROVED IN US FOR HER2+ SOLID TUMOURS |
| 6-K | 2024-04-05 | 2024-04-05 | IMFINZI IMPROVED OS & PFS IN LIMITED-STAGE SCLC |
| 6-K | 2024-04-02 | 2024-04-02 | TOTAL VOTING RIGHTS |
| 6-K | 2024-04-02 | 2024-04-02 | FDA ACCEPTS DATO-DXD BLA FOR BREAST CANCER |
| 6-K | 2024-04-02 | 2024-04-02 | VOYDEYA APPROVED IN US |
| 6-K | 2024-03-25 | 2024-03-25 | ULTOMIRIS APPROVED IN THE US FOR NMOSD |
| 6-K | 2024-03-19 | 2024-03-19 | FORM 6-K |
| 6-K | 2024-03-14 | 2024-03-14 | ASTRAZENECA TO ACQUIRE AMOLYT |
| 6-K | 2024-03-12 | 2024-03-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-03-07 | 2024-03-07 | FORM 6-K |
| 6-K | 2024-03-07 | 2024-03-07 | NOTICE OF AGM |
| 6-K | 2024-03-06 | 2024-03-06 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-03-06 | 2024-03-06 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-03-04 | 2024-03-04 | EMA VALIDATES DATO-DXD MAAS FOR NSQ NSCLC AND BC |
| 6-K | 2024-03-01 | 2024-03-01 | TOTAL VOTING RIGHTS |
| 6-K | 2024-02-26 | 2024-02-26 | FORM 6-K |
| 6-K | 2024-02-26 | 2024-02-26 | VOYDEYA RECOMMENDED FOR EU APPROVAL |
| 6-K | 2024-02-22 | 2024-02-22 | FORM 6-K |
| 6-K | 2024-02-22 | 2024-02-22 | ASTRAZENECA PRICES A $5BN BOND OFFERING |
| 6-K | 2024-02-22 | 2024-02-22 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-02-21 | 2024-02-21 | FILING OF FORM 20-F WITH SEC |
| 20-F | 2023-12-31 | 2024-02-20 | FORM 20-F |
| 6-K | 2024-02-19 | 2024-02-20 | TAGRISSO IMPROVED PFS IN STAGE III LUNG CANCER |
| 6-K | 2024-02-20 | 2024-02-20 | FDA ACCEPTS DATO-DXD BLA FOR NONSQUAMOUS NSCLC |
| 6-K | 2024-02-20 | 2024-02-20 | TAGRISSO PLUS CHEMO APPROVED IN US FOR LUNG CANCER |
| 6-K | 2024-02-20 | 2024-02-20 | ASTRAZENECA COMPLETES ACQUISITION OF ICOSAVAX |
| 6-K | 2024-02-20 | 2024-02-20 | FORM 6-K |
| 6-K | 2024-02-20 | 2024-02-20 | ANNUAL FINANCIAL REPORT |
| 6-K | 2024-02-20 | 2024-02-20 | FORM 6-K |
| 6-K | 2024-02-08 | 2024-02-08 | FINAL RESULTS |
| 6-K | 2024-02-01 | 2024-02-01 | TOTAL VOTING RIGHTS |
| 6-K | 2024-01-19 | 2024-01-19 | FORM 6-K |
| 6-K | 2024-01-02 | 2024-01-02 | TOTAL VOTING RIGHTS |
| 6-K | 2023-12-27 | 2023-12-27 | ASTRAZENECA ACQUIRES GRACELL |
| 6-K | 2023-12-26 | 2023-12-26 | FORM 6-K |
| 6-K | 2023-12-22 | 2023-12-22 | WAINUA (EPLONTERSEN) GRANTED FIRST US FDA APPROVAL |
| 6-K | 2023-12-14 | 2023-12-14 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-12-12 | 2023-12-12 | FORM 6-K |
| 6-K | 2023-12-12 | 2023-12-12 | ASTRAZENECA TO ACQUIRE ICOSAVAX |
| 6-K | 2023-12-01 | 2023-12-01 | DISCONTINUATION OF TWO CRYSTALIZE EVIDENCE TRIALS |
| 6-K | 2023-12-01 | 2023-12-01 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2023-12-01 | 2023-12-01 | TOTAL VOTING RIGHTS |
| 6-K | 2023-11-24 | 2023-11-24 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-11-17 | 2023-11-17 | TRUQAP APPROVED IN US FOR HR+ BREAST CANCER |
| 6-K | 2023-11-14 | 2023-11-14 | UPDATE ON PACIFIC-2 PHASE III TRIAL FOR IMFINZI |
| 6-K | 2023-11-09 | 2023-11-09 | AGREEMENT WITH ECCOGENE FOR CLINICAL STAGE GLP-1RA |
| 6-K | 2023-11-09 | 2023-11-09 | DIRECTOR DECLARATION |
| 6-K | 2023-11-09 | 2023-11-09 | IMFINZI COMBINATION IMPROVES PFS IN LIVER CANCER |
| 6-K | 2023-11-02 | 2023-11-09 | 9M AND Q3 2023 RESULTS |
| 6-K | 2023-11-01 | 2023-11-01 | ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTIS |
| 6-K | 2023-11-01 | 2023-11-01 | TOTAL VOTING RIGHTS |
| 6-K | 2023-10-03 | 2023-10-03 | ASTRAZENECA SETTLES NEXIUM LIABILITY LITIGATIONS |
| 6-K | 2023-10-02 | 2023-10-02 | TOTAL VOTING RIGHTS |
| 6-K | 2023-09-22 | 2023-09-25 | DATO-DXD IMPROVED PFS IN BREAST CANCER |
| 6-K | 2023-09-20 | 2023-09-20 | ALEXION COMPLETES PFIZER GENE THERAPY AGREEMENT |
| 6-K | 2023-09-15 | 2023-09-15 | ENHERTU RECOMMENDED IN EU FOR HER2-MUTANT NSCLC |
| 6-K | 2023-09-11 | 2023-09-11 | FASENRA PHASE III EGPA TRIAL MET PRIMARY ENDPOINT |
| 6-K | 2023-09-06 | 2023-09-06 | UPDATE ON US REVIEW OF ULTOMIRIS FOR NMOSD |
| 6-K | 2023-09-01 | 2023-09-01 | TOTAL VOTING RIGHTS |
| 6-K | 2023-08-01 | 2023-08-01 | TOTAL VOTING RIGHTS |
| 6-K | 2023-07-28 | 2023-07-28 | ALEXION ENTERS GENE THERAPY AGREEMENT WITH PFIZER |
| 6-K | 2023-06-30 | 2023-07-28 | FORM 6K |
| 6-K | 2023-07-17 | 2023-07-17 | BEYFORTUS APPROVED IN US FOR INFANT RSV PREVENTION |
| 6-K | 2023-07-03 | 2023-07-03 | TOTAL VOTING RIGHTS |
| 6-K | 2023-07-03 | 2023-07-03 | DATO-DXD SIGNIFICANTLY IMPROVED PFS IN LUNG CANCER |
| 6-K | 2023-06-09 | 2023-06-09 | ASTRAZENECA AGREEMENT WITH QUELL THERAPEUTICS |
| 6-K | 2023-06-09 | 2023-06-09 | NIRSEVIMAB RECOMMENDED FOR INFANT RSV PROTECTION |
| 6-K | 2023-06-02 | 2023-06-02 | IMFINZI IMPROVED PCR IN GASTRIC AND GEJ CANCERS |
| 6-K | 2023-06-01 | 2023-06-01 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2023-06-01 | 2023-06-01 | TOTAL VOTING RIGHTS |
| 6-K | 2023-06-01 | 2023-06-01 | LYNPARZA APPROVED IN US FOR BRCAM PROSTATE CANCER |
| 6-K | 2023-05-26 | 2023-05-26 | IMFINZI + LYNPARZA PROLONGED PFS IN ENDOMETRIAL CANCER |
| 6-K | 2023-05-22 | 2023-05-22 | DIRECTORATE CHANGE |
| 6-K | 2023-05-17 | 2023-05-17 | TAGRISSO PLUS CHEMO IMPROVED PFS IN LUNG CANCER |
| 6-K | 2023-05-09 | 2023-05-09 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-05-09 | 2023-05-09 | FARXIGA EXTENDED IN THE US FOR HEART FAILURE |
| 6-K | 2023-05-02 | 2023-05-02 | TOTAL VOTING RIGHTS |
| 6-K | 2023-05-02 | 2023-05-02 | ODAC VOTE ON LYNPARZA COMBO IN PROSTATE CANCER |
| 6-K | 2023-05-02 | 2023-05-02 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-04-27 | 2023-04-27 | FORM 6-K |
| 6-K | 2023-04-27 | 2023-04-27 | 1ST QUARTER RESULTS |
| 6-K | 2023-04-27 | 2023-04-27 | RESULT OF AGM |
| 6-K | 2023-04-27 | 2023-04-27 | BOARD COMMITTEE CHANGES |
| 6-K | 2023-04-26 | 2023-04-26 | DIRECTOR DECLARATION |
| 6-K | 2023-04-11 | 2023-04-11 | UPDATE TO ARRANGEMENTS WITH SOBI AND SANOFI |
| 6-K | 2023-04-05 | 2023-04-05 | LYNPARZA + IMFINZI MET ENDPOINT IN OVARIAN CANCER |
| 6-K | 2023-04-03 | 2023-04-03 | ULTOMIRIS RECOMMENDED FOR NMOSD EU APPROVAL |
| 6-K | 2023-04-03 | 2023-04-03 | TOTAL VOTING RIGHTS |
| 6-K | 2023-03-30 | 2023-03-30 | ASTRAZENECA COMPLETES KYM AGREEMENT FOR CMG901 |
| 6-K | 2023-03-27 | 2023-03-27 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-03-22 | 2023-03-22 | FORM 6-K |
| 6-K | 2023-03-22 | 2023-03-22 | NOTICE OF AGM |
| 6-K | 2023-03-09 | 2023-03-09 | IMFINZI IMPROVED EFS IN RESECTABLE LUNG CANCER |
| 6-K | 2023-03-08 | 2023-03-08 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-03-08 | 2023-03-08 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-03-06 | 2023-03-06 | ENHERTU DESTINY-PANTUMOR02 SHOWS POSITIVE RESULTS |
| 6-K | 2023-03-03 | 2023-03-03 | FORM 6-K |
| 6-K | 2023-03-01 | 2023-03-01 | TOTAL VOTING RIGHTS |
| 6-K | 2023-03-01 | 2023-03-01 | ASTRAZENECA PRICES A $2.25BN BOND OFFERING |
| 6-K | 2023-02-24 | 2023-02-24 | ASTRAZENECA PRICES A EUR1.5BN BOND OFFERING |
| 6-K | 2023-02-24 | 2023-02-24 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-02-24 | 2023-02-24 | ASTRAZENECA ACQUIRES CINCOR FOR CARDIORENAL ASSET |
| 6-K | 2023-02-23 | 2023-02-23 | ASTRAZENECA ENTERS AGREEMENT WITH KYM FOR CMG901 |
| 6-K | 2023-02-22 | 2023-02-22 | FILING OF FORM 20-F WITH SEC |
| 20-F | 2022-12-31 | 2023-02-21 | FORM 20-F |
| 6-K | 2023-02-21 | 2023-02-21 | FORM 6-K |
| 6-K | 2023-02-21 | 2023-02-21 | ANNUAL FINANCIAL REPORT |
| 6-K | 2023-02-13 | 2023-02-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-02-13 | 2023-02-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-02-09 | 2023-02-09 | FINAL RESULTS |
| 6-K | 2023-02-01 | 2023-02-01 | TOTAL VOTING RIGHTS |
| 6-K | 2023-01-26 | 2023-01-26 | UPDATE ON EVUSHELD US EUA |
| 6-K | 2023-01-17 | 2023-01-17 | ACQUISITION OF NEOGENE THERAPEUTICS COMPLETED |
| 6-K | 2023-01-11 | 2023-01-11 | AIRSUPRA (PT027) APPROVED IN US FOR ASTHMA |
| 6-K | 2023-01-09 | 2023-01-09 | ASTRAZENECA ACQUIRE CINCOR FOR CARDIORENAL ASSET |
| 6-K | 2023-01-03 | 2023-01-03 | TOTAL VOTING RIGHTS |
| 6-K | 2022-12-30 | 2022-12-30 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-12-28 | 2022-12-28 | CALQUENCE JAPAN APPROVAL FOR TREATMENT-NAIVE CLL |
| 6-K | 2022-12-28 | 2022-12-28 | IMFINZI, IMJUDO APPROVED IN JAPAN FOR 3 CANCERS |
| 6-K | 2022-12-21 | 2022-12-21 | LYNPARZA APPROVED IN EU FOR PROSTATE CANCER |
| 6-K | 2022-12-21 | 2022-12-21 | IMFINZI APPROVED IN EU FOR BILIARY TRACT CANCER |
| 6-K | 2022-12-19 | 2022-12-19 | IMFINZI PLUS IMJUDO RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR THE TREATMENT |
| 6-K | 2022-12-19 | 2022-12-19 | FORXIGA CHMP OPINION FOR SYMPTOMATIC CHRONIC HF |
| 6-K | 2022-12-19 | 2022-12-19 | ENHERTU RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR PATIENTS WITH HER2-LOW ME |
| 6-K | 2022-12-19 | 2022-12-19 | ENHERTU APPROVED IN THE EU FOR PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE AD |
| 6-K | 2022-12-19 | 2022-12-19 | UPDATE ON PEARL PHASE III TRIAL OF IMFINZI MONOTHERAPY IN STAGE IV NON-SMALL CEL |
| 6-K | 2022-12-15 | 2022-12-15 | UPDATE ON US REVIEW OF LYNPARZA PROPEL SNDA |
| 6-K | 2022-12-08 | 2022-12-08 | CAPIVASERTIB PFS IN HR-POSITIVE BREAST CANCER |
| 6-K | 2022-12-01 | 2022-12-01 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2022-12-01 | 2022-12-01 | TOTAL VOTING RIGHTS |
| 6-K | 2022-11-30 | 2022-11-30 | ASTRAZENECA ANNOUNCES SALE OF WEST CHESTER SITE |
| 6-K | 2022-11-29 | 2022-11-29 | ASTRAZENECA TO ACQUIRE NEOGENE THERAPEUTICS |
| 6-K | 2022-11-23 | 2022-11-23 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-11-14 | 2022-11-14 | ENHERTU RECOMMENDED FOR EU APPROVAL IN GASTRIC |
| 6-K | 2022-11-14 | 2022-11-14 | IMFINZI RECOMMENDED FOR APPROVAL IN THE EU FOR BTC |
| 6-K | 2022-11-14 | 2022-11-14 | LYNPARZA COMBO RECOMMENDED IN THE EU FOR MCRPC |
| 6-K | 2022-11-11 | 2022-11-14 | IMFINZI + IMJUDO APPROVED IN US FOR LUNG CANCER |
| 6-K | 2022-11-10 | 2022-11-10 | YTD AND Q3 2022 RESULTS |
| 6-K | 2022-11-09 | 2022-11-09 | FDA ADVISORY COMMITTEE RECOMMENDS PT027 IN ASTHMA |
| 6-K | 2022-11-04 | 2022-11-04 | BEYFORTUS (NIRSEVIMAB) APPROVED IN EU |
| 6-K | 2022-11-01 | 2022-11-01 | TOTAL VOTING RIGHTS |
| 6-K | 2022-10-26 | 2022-10-26 | CAPIVASERTIB PHASE III TRIAL MET PRIMARY ENDPOINTS |
| 6-K | 2022-10-25 | 2022-10-25 | UPDATE ON MESSINA PHASE III TRIAL |
| 6-K | 2022-10-24 | 2022-10-24 | IMFINZI + IMJUDO APPROVED IN ADVANCED LIVER CANCER |
| 6-K | 2022-10-03 | 2022-10-03 | TOTAL VOTING RIGHTS |
| 6-K | 2022-09-30 | 2022-09-30 | BOARD COMMITTEE CHANGES |
| 6-K | 2022-09-27 | 2022-09-27 | KOSELUGO APPROVED IN JAPAN FOR NF1 |
| 6-K | 2022-09-27 | 2022-09-27 | TEZSPIRE APPROVED IN JAPAN FOR SEVERE ASTHMA |
| 6-K | 2022-09-23 | 2022-09-23 | ULTOMIRIS APPROVED IN EU FOR GMG |
| 6-K | 2022-09-22 | 2022-09-22 | LYNPARZA APPROVED IN CHINA FOR OVARIAN CANCER |
| 6-K | 2022-09-21 | 2022-09-21 | TEZSPIRE APPROVED IN THE EU FOR SEVERE ASTHMA |
| 6-K | 2022-09-20 | 2022-09-20 | EVUSHELD APPROVED IN EU FOR COVID-19 TREATMENT |
| 6-K | 2022-09-16 | 2022-09-16 | NIRSEVIMAB RECOMMENDED FOR APPROVAL IN EU BY CHMP |
| 6-K | 2022-09-16 | 2022-09-16 | DANICOPAN PHASE III TRIAL MET PRIMARY ENDPOINT |
| 6-K | 2022-09-16 | 2022-09-16 | EVUSHELD POSITIVE CHMP OPINION IN EU |
| 6-K | 2022-09-06 | 2022-09-06 | FORXIGA APPROVED IN CHINA FOR CKD |
| 6-K | 2022-09-06 | 2022-09-06 | IMFINZI APPROVED IN US FOR BILIARY TRACT CANCER |
| 6-K | 2022-09-01 | 2022-09-01 | TOTAL VOTING RIGHTS |
| 6-K | 2022-08-30 | 2022-08-30 | FARXIGA SHOWS CV MORTALITY BENEFIT ACROSS EF RANGE |
| 6-K | 2022-08-30 | 2022-08-30 | EVUSHELD APPROVED FOR COVID-19 IN JAPAN |
| 6-K | 2022-08-30 | 2022-08-30 | FARXIGA REDUCED RISK OF CV DEATH OR WORSENING HF |
| 6-K | 2022-08-25 | 2022-08-25 | LYNPARZA APPROVED IN JAPAN FOR EARLY BREAST CANCER |
| 6-K | 2022-08-25 | 2022-08-25 | TAGRISSO APPROVED IN JAPAN FOR EARLY LUNG CANCER |
| 6-K | 2022-08-25 | 2022-08-25 | ULTOMIRIS APPROVED IN JAPAN FOR GMG |
| 6-K | 2022-08-16 | 2022-08-16 | LYNPARZA GRANTED FDA PRIORITY REVIEW FOR PROPEL |
| 6-K | 2022-08-15 | 2022-08-15 | ENHERTU IMPROVED PFS IN MBC IN DESTINY-BREAST02 |
| 6-K | 2022-08-12 | 2022-08-12 | ENHERTU APPROVED IN US FOR HER2-MUTANT NSCLC |
| 6-K | 2022-08-11 | 2022-08-11 | ACQUISITION OF TENEOTWO COMPLETED |
| 6-K | 2022-08-08 | 2022-08-08 | ENHERTU APPROVED IN THE US FOR HER2-LOW MBC |
| 6-K | 2022-08-04 | 2022-08-04 | LYNPARZA APPROVED IN EU FOR EARLY BREAST CANCER |
| 6-K | 2022-08-01 | 2022-08-01 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-08-01 | 2022-08-01 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-08-01 | 2022-08-01 | TOTAL VOTING RIGHTS |
| 6-K | 2022-06-30 | 2022-07-29 | FORM 6-K |
| 6-K | 2022-07-29 | 2022-07-29 | CHAIR SUCCESSION |
| 6-K | 2022-07-25 | 2022-07-25 | TEZSPIRE RECOMMENDED FOR EU APPROVAL IN ASTHMA |
| 6-K | 2022-07-25 | 2022-07-25 | ULTOMIRIS RECOMMENDED FOR EU APPROVAL FOR GMG |
| 6-K | 2022-07-25 | 2022-07-25 | ENHERTU GRANTED PRIORITY REVIEW FOR HER2-LOW MBC |
| 6-K | 2022-07-19 | 2022-07-19 | ENHERTU APPROVED IN EU FOR HER2-POSITIVE MBC |
| 6-K | 2022-07-05 | 2022-07-05 | ASTRAZENECA TO ACQUIRE TENEOTWO AND T CELL ENGAGER |
| 6-K | 2022-07-01 | 2022-07-01 | TOTAL VOTING RIGHTS |
| 6-K | 2022-06-30 | 2022-06-30 | IMFINZI IMPROVED PCR IN RESECTABLE LUNG CANCER |
| 6-K | 2022-06-27 | 2022-06-27 | LYNPARZA RECOMMENDED IN EU FOR EARLY BREAST CANCER |
| 6-K | 2022-06-27 | 2022-06-27 | ENHERTU RECOMMENDED FOR BREAST CANCER EU APPROVAL |
| 6-K | 2022-06-21 | 2022-06-21 | EPLONTERSEN PH III TRIAL MET CO-PRIMARY ENDPOINTS |
| 6-K | 2022-06-06 | 2022-06-06 | ENHERTU EFFICACY RESULTS IN HER2-LOW BREAST CANCER |
| 6-K | 2022-06-01 | 2022-06-01 | TOTAL VOTING RIGHTS |
| 6-K | 2022-06-01 | 2022-06-01 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2022-05-20 | 2022-05-20 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-05-09 | 2022-05-09 | APPOINTMENT OF JOINT CORPORATE BROKERS |
| 6-K | 2022-05-06 | 2022-05-06 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-05-05 | 2022-05-05 | ULTOMIRIS NMOSD PH. III TRIAL MET PRIMARY ENDPOINT |
| 6-K | 2022-05-05 | 2022-05-05 | ENHERTU APPROVED IN US FOR 2L HER2+ BREAST CANCER |
| 6-K | 2022-05-05 | 2022-05-05 | FARXIGA HFPEF PHASE III TRIAL MET PRIMARY ENDPOINT |
| 6-K | 2022-05-04 | 2022-05-04 | IMFINZI COMBO GRANTED PRIORITY REVIEW FOR BTC |
| 6-K | 2022-05-03 | 2022-05-03 | TOTAL VOTING RIGHTS |
| 6-K | 2022-04-29 | 2022-04-29 | FIRST QUARTER 2022 RESULTS |
| 6-K | 2022-04-29 | 2022-04-29 | ASTRAZENECA PLANS NEW R&D CENTRE IN MASSACHUSETTS |
| 6-K | 2022-04-29 | 2022-04-29 | RESULT OF AGM |
| 6-K | 2022-04-28 | 2022-04-28 | ULTOMIRIS APPROVED IN THE US FOR ADULTS WITH GMG |
| 6-K | 2022-04-27 | 2022-04-27 | ENHERTU GRANTED BTD FOR HER2-LOW BREAST CANCER |
| 6-K | 2022-04-25 | 2022-04-25 | TREMELIMUMAB US PRIORITY REVIEW FOR IMFINZI COMBO |
| 6-K | 2022-04-19 | 2022-04-19 | ENHERTU GRANTED PRIORITY REVIEW FOR HER2M NSCLC |
| 6-K | 2022-04-01 | 2022-04-01 | TOTAL VOTING RIGHTS |
| 6-K | 2022-03-29 | 2022-03-29 | ONDEXXYA APPROVED IN JAPAN FOR FXAI REVERSAL |
| 6-K | 2022-03-28 | 2022-03-28 | EVUSHELD APPROVED IN THE EU FOR COVID-19 |
| 6-K | 2022-03-25 | 2022-03-25 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-03-24 | 2022-03-24 | EVUSHELD POSITIVE EU CHMP OPINION |
| 6-K | 2022-03-24 | 2022-03-24 | UPDATE ON CALLA PHASE III TRIAL OF CONCURRENT USE OF IMFINZI AND CHEMORADIOTHERA |
| 6-K | 2022-03-23 | 2022-03-23 | FORM 6-K |
| 6-K | 2022-03-23 | 2022-03-23 | NOTICE OF AGM |
| 6-K | 2022-03-17 | 2022-03-17 | SETTLEMENT OF PATENT LITIGATION FOR ULTOMIRIS |
| 6-K | 2022-03-14 | 2022-03-14 | LYNPARZA APPROVED IN US FOR EARLY BREAST CANCER |
| 6-K | 2022-03-14 | 2022-03-14 | UPDATE ON US REVIEW OF FASENRA IN NASAL POLYPS |
| 6-K | 2022-03-09 | 2022-03-09 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-03-07 | 2022-03-07 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-03-01 | 2022-03-01 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-03-01 | 2022-03-01 | TOTAL VOTING RIGHTS |
| 6-K | 2022-03-01 | 2022-03-01 | ASTRAZENECA AND NEURIMMUNE CLOSE DEAL FOR NI006 |
| 6-K | 2022-02-23 | 2022-02-23 | FILING OF FORM 20-F WITH SEC |
| 6-K | 2022-02-22 | 2022-02-22 | ENHERTU IMPROVES PFS AND OS IN HER2-LOW BC |
| 20-F | 2021-12-31 | 2022-02-22 | FORM 20F |
| 6-K | 2022-02-22 | 2022-02-22 | CHAIR SUCCESSION PLANNING UPDATE AND ANNUAL REPORT |
| 6-K | 2022-02-16 | 2022-02-16 | SAPHNELO APPROVED IN EU FOR SLE |
| 6-K | 2022-02-15 | 2022-02-15 | LYNPARZA COMBO DELAYS PROGRESSION RISK IN PROSTATE |
| 6-K | 2022-02-11 | 2022-02-11 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-02-10 | 2022-02-10 | AZN: FULL YEAR AND Q4 2021 RESULTS |
| 6-K | 2022-02-01 | 2022-02-01 | TOTAL VOTING RIGHTS |
| 6-K | 2022-01-19 | 2022-01-19 | IMFINZI IMPROVES SURVIVAL IN BILIARY TRACT CANCER |
| 6-K | 2022-01-19 | 2022-01-19 | IMFINZI COMBO SHOWS UNPRECEDENTED SURVIVAL IN HCC |
| 6-K | 2022-01-18 | 2022-01-18 | ENHERTU GRANTED PRIORITY REVIEW FOR BREAST CANCER |
| 6-K | 2022-01-07 | 2022-01-07 | ASTRAZENECA AND NEURIMMUNE SIGN DEAL FOR NI006 |
| 6-K | 2022-01-05 | 2022-01-05 | TRANSFER OF RIGHTS TO EKLIRA, DUAKLIR COMPLETED |
| 6-K | 2022-01-04 | 2022-01-04 | TOTAL VOTING RIGHTS |
| 6-K | 2021-12-29 | 2021-12-29 | ASTRAZENECA AND IONIS CLOSE EPLONTERSEN DEAL |
| 6-K | 2021-12-21 | 2021-12-21 | ULTOMIRIS ACCEPTED FOR FDA PRIORITY REVIEW FOR GMG |
| 6-K | 2021-12-20 | 2021-12-20 | TEZSPIRE APPROVED IN THE US FOR SEVERE ASTHMA |
| 6-K | 2021-12-20 | 2021-12-20 | SAPHNELO RECOMMENDED FOR EU APPROVAL FOR SLE |
| 6-K | 2021-12-15 | 2021-12-15 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2021-12-09 | 2021-12-09 | EVUSHELD US FDA EUA |
| 6-K | 2021-12-07 | 2021-12-07 | ASTRAZENECA, IONIS TO COLLABORATE ON EPLONTERSEN |
| 6-K | 2021-12-01 | 2021-12-01 | TOTAL VOTING RIGHTS |
| 6-K | 2021-12-01 | 2021-12-01 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2021-11-30 | 2021-11-30 | LYNPARZA GRANTED FDA PRIORITY REVIEW FOR OLYMPIA |
| 6-K | 2021-11-15 | 2021-11-15 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2021-11-12 | 2021-11-12 | AZN: YEAR TO DATE AND Q3 2021 RESULTS |
| 6-K | 2021-11-01 | 2021-11-01 | ASTRAZENECA TO TRANSFER RIGHTS TO EKLIRA, DUAKLIR |
| 6-K | 2021-11-01 | 2021-11-01 | TOTAL VOTING RIGHTS |
| 6-K | 2021-10-25 | 2021-10-25 | IMFINZI IMPROVED SURVIVAL IN BILIARY TRACT CANCER |
| 6-K | 2021-10-18 | 2021-10-18 | AZ RECOMMENDS ADS HOLDERS REJECT MINI-TENDER OFFER |
| 6-K | 2021-10-15 | 2021-10-15 | IMFINZI & TREMELIMUMAB IMPROVED OS IN LIVER CANCER |
| 6-K | 2021-10-12 | 2021-10-12 | AZD7442 PHIII TRIAL POSITIVE IN COVID OUTPATIENTS |
| 6-K | 2021-10-04 | 2021-10-04 | ENHERTU GRANTED BTD FOR BREAST CANCER |
| 6-K | 2021-10-01 | 2021-10-01 | TOTAL VOTING RIGHTS |
| 6-K | 2021-09-30 | 2021-09-30 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2021-09-29 | 2021-09-29 | ASTRAZENECA TO FULLY ACQUIRE CAELUM BIOSCIENCES |
| 6-K | 2021-09-28 | 2021-09-28 | SAPHNELO APPROVED IN JAPAN FOR SLE |
| 6-K | 2021-09-24 | 2021-09-24 | LYNPARZA PROPEL TRIAL MEETS PRIMARY ENDPOINT |
| 6-K | 2021-09-23 | 2021-09-23 | BOARD COMMITTEE CHANGE |
| 6-K | 2021-09-23 | 2021-09-23 | NEW SUSTAINABILITY COMMITTEE OF THE BOARD |
| 6-K | 2021-09-21 | 2021-09-21 | ASTRAZENECA $360M IRISH MANUFACTURING INVESTMENT |
| 6-K | 2021-09-20 | 2021-09-20 | ENHERTU REDUCED RISK OF DISEASE PROGRESSION BY 72% |
| 6-K | 2021-09-09 | 2021-09-09 | IMFINZI IMPROVES SURVIVAL IN NSCLC IN POSEIDON |
| 6-K | 2021-09-09 | 2021-09-09 | FIXED-DOSE COMBINATION OF ALBUTEROL AND BUDESONIDE (PT027) DEMONSTRATED SIGNIFIC |
| 6-K | 2021-09-03 | 2021-09-03 | ULTOMIRIS APPROVED IN EU FOR CHILDREN WITH PNH |
| 6-K | 2021-09-01 | 2021-09-01 | TOTAL VOTING RIGHTS |
| 6-K | 2021-08-26 | 2021-08-26 | FORXIGA APPROVED IN JAPAN FOR CKD |
| 6-K | 2021-08-26 | 2021-08-26 | ALXN1840 WILSON PHASE III MET PRIMARY ENDPOINT |
| 6-K | 2021-08-20 | 2021-08-20 | AZD7442 PROPHYLAXIS TRIAL MET PRIMARY ENDPOINT |
| 6-K | 2021-08-20 | 2021-08-20 | UPDATE ON ULTOMIRIS PHASE III ALS TRIAL |
| 6-K | 2021-08-16 | 2021-08-16 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2021-08-11 | 2021-08-11 | UPDATE ON US REVIEW OF ROXADUSTAT |
| 6-K | 2021-08-09 | 2021-08-09 | FORXIGA APPROVED IN THE EU FOR CKD |
| 6-K | 2021-08-09 | 2021-08-09 | ENHERTU HEAD-TO-HEAD TRIAL MEETS PRIMARY ENDPOINT |
| 6-K | 2021-08-02 | 2021-08-02 | TOTAL VOTING RIGHTS |
| 6-K | 2021-08-02 | 2021-08-02 | SAPHNELO APPROVED IN THE US FOR SLE |
| 6-K | 2021-06-30 | 2021-07-30 | FORM 6-K |
| 6-K | 2021-07-26 | 2021-07-26 | ULTOMIRIS RECOMMENDED IN EU FOR CHILDREN WITH PNH |
| 6-K | 2021-07-22 | 2021-07-22 | DIRECTORATE CHANGE |
| 6-K | 2021-07-21 | 2021-07-21 | FORM 6-K |
| 6-K | 2021-07-21 | 2021-07-21 | ACQUISITION OF ALEXION COMPLETED |
| 6-K | 2021-07-21 | 2021-07-21 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2021-07-21 | 2021-07-21 | TOTAL VOTING RIGHTS |
| 6-K | 2021-07-19 | 2021-07-19 | IMFINZI APPROVED IN CHINA FOR EXTENSIVE-STAGE SCLC |
| 6-K | 2021-07-16 | 2021-07-16 | STATUS ON US FDA ADVISORY COMMITTEE FOR ROXADUSTAT |
| 6-K | 2021-07-14 | 2021-07-14 | ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE UK |
| 6-K | 2021-07-08 | 2021-07-08 | TEZEPELUMAB GRANTED FDA PRIORITY REVIEW FOR ASTHMA |
| 6-K | 2021-07-06 | 2021-07-06 | ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE EU |
| 6-K | 2021-07-01 | 2021-07-01 | TOTAL VOTING RIGHTS |
| 6-K | 2021-06-28 | 2021-06-28 | FORXIGA RECOMMENDED IN EU FOR PATIENTS WITH CKD |
| 6-K | 2021-06-28 | 2021-06-28 | NIRSEVIMAB PHII/III TRIAL CONFIRMS SAFETY PROFILE |
| 6-K | 2021-06-24 | 2021-06-24 | LYNPARZA APPROVED IN CHINA FOR PROSTATE CANCER |
| 6-K | 2021-06-23 | 2021-06-23 | ORPATHYS APPROVED IN CHINA FOR LUNG CANCER |
| 6-K | 2021-06-22 | 2021-06-22 | KOSELUGO APPROVED IN THE EU FOR CHILDREN WITH NF1 |
| 6-K | 2021-06-15 | 2021-06-15 | UPDATE ON AZD7442 STORM CHASER TRIAL |
| 6-K | 2021-06-07 | 2021-06-07 | CALQUENCE HEAD-TO-HEAD RESULTS VERSUS IBRUTINIB |
| 6-K | 2021-06-04 | 2021-06-04 | ASTRAZENECA APPOINTS NEW CHIEF FINANCIAL OFFICER |
| 6-K | 2021-06-04 | 2021-06-04 | LYNPARZA REDUCED RECURRENCE RISK IN BREAST CANCER |
| 6-K | 2021-06-02 | 2021-06-02 | PUBLICATION OF FINAL TERMS |
| 6-K | 2021-06-01 | 2021-06-01 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2021-06-01 | 2021-06-01 | TOTAL VOTING RIGHTS |
| 6-K | 2021-05-28 | 2021-05-28 | TAGRISSOAPPROVED IN THE EU FOR THE ADJUVANT TREATMENT OFPATIENTS WITH EARLY-STAG |
| 6-K | 2021-05-28 | 2021-05-28 | FORM 6-K |
| 6-K | 2021-05-27 | 2021-05-27 | ASTRAZENECA PRICES A EUR800M BOND OFFERING |
| 6-K | 2021-05-26 | 2021-05-26 | ASTRAZENECA PRICES A $7BN BOND OFFERING |
| 6-K | 2021-05-26 | 2021-05-26 | FORM 6-K |
| 6-K | 2021-05-25 | 2021-05-25 | EMTN PROGRAMME UPDATE - PUBLICATION OF PROSPECTUS |
| 6-K | 2021-05-24 | 2021-05-24 | FORM 6-K |
| 6-K | 2021-05-21 | 2021-05-21 | ASTRAZENECA COVID-19 VACCINE VAXZEVRIA AUTHORISED FOR EMERGENCY USE IN JAPAN |
| 6-K | 2021-05-18 | 2021-05-18 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2021-05-11 | 2021-05-11 | SHAREHOLDERS VOTE IN FAVOUR OF ALEXION ACQUISITION |
| 6-K | 2021-05-11 | 2021-05-11 | RESULT OF AGM |
| 6-K | 2021-05-07 | 2021-05-07 | IMFINZI + TREMELIMUMAB SHOWED SURVIVAL IN POSEIDON |
| 6-K | 2021-05-04 | 2021-05-04 | FARXIGA APPROVED IN THE US FOR CKD |
| 6-K | 2021-05-04 | 2021-05-04 | TOTAL VOTING RIGHTS |
| 6-K | 2021-04-30 | 2021-04-30 | AZN: FIRST QUARTER 2021 RESULTS |
| 6-K | 2021-04-26 | 2021-04-26 | NIRSEVIMAB PHASE III TRIAL MET PRIMARY ENDPOINT |
| 6-K | 2021-04-26 | 2021-04-26 | TAGRISSO ADJUVANT RECEIVES POSITIVE CHMP OPINION |
| 6-K | 2021-04-26 | 2021-04-26 | SELUMETINIB RECOMMENDED FOR EU APPROVAL IN NF1 |
| 6-K | 2021-04-16 | 2021-04-16 | US CLEARANCE OF PROPOSED ACQUISITION OF ALEXION |
| 6-K | 2021-04-14 | 2021-04-14 | TAGRISSO APPROVED IN CHINA IN EARLY LUNG CANCER |
| 6-K | 2021-04-12 | 2021-04-12 | FORM 6-K |
| 6-K | 2021-04-12 | 2021-04-12 | UPDATE ON FARXIGA COVID-19 DARE-19 PHASE III TRIAL |
| 6-K | 2021-04-12 | 2021-04-12 | CIRCULAR AND NOTICE OF GENERAL MEETING |
| 6-K | 2021-04-01 | 2021-04-01 | TOTAL VOTING RIGHTS |
| 6-K | 2021-03-30 | 2021-03-30 | FORM 6-K |
| 6-K | 2021-03-30 | 2021-03-30 | NOTICE OF AGM |
| 6-K | 2021-03-25 | 2021-03-25 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2021-03-25 | 2021-03-25 | AZD1222 US PH3 PRIMARY ANALYSIS CONFIRMS EFFICACY |
| 6-K | 2021-03-22 | 2021-03-22 | ASTRAZENECA US VACCINE TRIAL MET PRIMARY ENDPOINT |
| 6-K | 2021-03-16 | 2021-03-16 | DIVESTMENT OF VIELA SHAREHOLDING COMPLETED |
| 6-K | 2021-03-16 | 2021-03-16 | US SUPPLY AGREEMENT FOR ADDITIONAL AZD7442 DOSES |
| 6-K | 2021-03-09 | 2021-03-09 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2021-03-04 | 2021-03-04 | DESIGNATION OF EU HOME MEMBER STATE FOR EU SECURITIES REGULATION PURPOSES |
| 6-K | 2021-03-03 | 2021-03-03 | US COURT DECISION FAVOURS SYMBICORT PATENTS |
| 6-K | 2021-03-02 | 2021-03-02 | FURTHER UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNE |
| 6-K | 2021-03-01 | 2021-03-01 | TRANSPARENCY DIRECTIVE VOTING RIGHTS AND CAPITAL |
| 6-K | 2021-02-22 | 2021-02-22 | VOLUNTARY WITHDRAWAL OF IMFINZI INDICATION IN ADVANCED BLADDER CANCER IN THE US |
| 6-K | 2021-02-17 | 2021-02-17 | LYNPARZA: IDMC RECOMMEND EARLY ANALYSIS OF OLYMPIA |
| 6-K | 2021-02-16 | 2021-02-16 | FILING OF FORM 20-F WITH SEC |
| 6-K | 2021-02-16 | 2021-02-16 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2021-02-16 | 2021-02-16 | ANNUAL FINANCIAL REPORT |
| 20-F | 2020-12-31 | 2021-02-16 | 20-F |
| 6-K | 2021-02-11 | 2021-02-11 | ASTRAZENECA NON-EXECUTIVE BOARD CHANGES |
| 6-K | 2021-02-11 | 2021-02-11 | AZN: FULL-YEAR 2020 RESULTS |
| 6-K | 2021-02-10 | 2021-02-10 | DIVESTMENT OF CRESTOR IN EUROPE COMPLETED |
| 6-K | 2021-02-05 | 2021-02-05 | UPDATE ON KESTREL PHASE III TRIAL FOR IMFINZI |
| 6-K | 2021-02-04 | 2021-02-04 | FORXIGA APPROVED IN CHINA FOR HEART FAILURE |
| 6-K | 2021-02-01 | 2021-02-01 | ASTRAZENECA AGREES TO DIVEST VIELA SHAREHOLDING |
| 6-K | 2021-02-01 | 2021-02-01 | TOTAL VOTING RIGHTS |
| 6-K | 2021-02-01 | 2021-02-01 | COVID-19 VACCINE AUTHORISED FOR USE BY THE EU |
| 6-K | 2021-01-29 | 2021-01-29 | COVID-19 VACCINE RECEIVES POSITIVE OPINION IN EU |
| 6-K | 2021-01-26 | 2021-01-26 | BLOCK LISTING APPLICATION |
| 6-K | 2021-01-26 | 2021-01-26 | SYMBICORT APPROVED IN CHINA FOR MILD ASTHMA |
| 6-K | 2021-01-25 | 2021-01-25 | CALQUENCE MET PRIMARY EFFICACY ENDPOINT IN HEAD-TO-HEAD TRIAL AGAINST IBRUTINIB |
| 6-K | 2021-01-25 | 2021-01-25 | CALQUENCE APPROVED IN JAPAN FOR CLL |
| 6-K | 2021-01-20 | 2021-01-20 | ENHERTU APPROVED IN THE EU FOR BREAST CANCER |
| 6-K | 2021-01-19 | 2021-01-19 | ENHERTU APPROVED IN THE US FOR GASTRIC CANCER |
| 6-K | 2021-01-15 | 2021-01-15 | IMFINZI APPROVED IN THE EU FOR LESS-FREQUENT, FIXED- DOSE USE IN UNRESECTABLE NO |
| 6-K | 2021-01-06 | 2021-01-06 | FARXIGA GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF PATIENTS WITH CHR |
| 6-K | 2021-01-04 | 2021-01-04 | TOTAL VOTING RIGHTS |
| 6-K | 2021-01-04 | 2021-01-04 | ATACAND DIVESTMENT TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES COMPLETED |
| 6-K | 2020-12-30 | 2020-12-30 | ASTRAZENECA'S COVID-19 VACCINE AUTHORISED IN UK |
| 6-K | 2020-12-29 | 2020-12-29 | LYNPARZA APPROVED IN JAPAN FOR THE TREATMENT OF ADVANCED OVARIAN, PROSTATE AND P |
| 6-K | 2020-12-21 | 2020-12-21 | TAGRISSO APPROVED IN THE US FOR THE ADJUVANT TREATMENT OF PATIENTS WITH EARLY-ST |
| 6-K | 2020-12-21 | 2020-12-21 | UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNEY DISEAS |
| 6-K | 2020-12-17 | 2020-12-17 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2020-12-16 | 2020-12-16 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2020-12-15 | 2020-12-15 | IMFINZI NEW DOSE RECEIVES POSITIVE EU CHMP OPINION |
| 6-K | 2020-12-14 | 2020-12-14 | TRIXEO AEROSPHERE APPROVED IN THE EU FOR COPD |
| 6-K | 2020-12-14 | 2020-12-14 | TRASTUZUMAB DERUXTECAN POSITIVE CHMP |
| 6-K | 2020-12-14 | 2020-12-14 | ASTRAZENECA TO ACQUIRE ALEXION PHARMACEUTICALS INC |
| 6-K | 2020-12-01 | 2020-12-01 | CRESTOR TO BE DIVESTED TO GRUNENTHAL IN EUROPE |
| 6-K | 2020-12-01 | 2020-12-01 | TOTAL VOTING RIGHTS |
| 6-K | 2020-12-01 | 2020-12-01 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2020-11-30 | 2020-11-30 | FORXIGA APPROVED IN JAPAN FOR CHRONIC HEART FAILURE |
| 6-K | 2020-11-23 | 2020-11-23 | AZD1222 VACCINE EFFECTIVE AGAINST COVID-19 |
| 6-K | 2020-11-20 | 2020-11-20 | IMFINZI NEW DOSING APPROVED IN THE US |
| 6-K | 2020-11-10 | 2020-11-10 | TEZEPELUMAB PHASE III TRIAL MET PRIMARY ENDPOINT |
| 6-K | 2020-11-09 | 2020-11-09 | CALQUENCE APPROVED IN THE EU FOR CLL |
| 6-K | 2020-11-06 | 2020-11-06 | BRILINTA APPROVED IN THE US IN STROKE |
| 6-K | 2020-11-05 | 2020-11-05 | FORXIGA APPROVED IN THE EU FOR HEART FAILURE |
| 6-K | 2020-11-05 | 2020-11-05 | LYNPARZAAPPROVED IN THE EU FOR THE TREATMENT OF BRCA- MUTATED METASTATIC CASTRAT |
| 6-K | 2020-11-05 | 2020-11-05 | LYNPARZA APPROVED IN THE EU AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F |
| 6-K | 2020-11-05 | 2020-11-05 | AZN: YEAR-TO-DATE AND Q3 2020 RESULTS |
| 6-K | 2020-11-02 | 2020-11-02 | TOTAL VOTING RIGHTS |
| 6-K | 2020-10-30 | 2020-10-30 | ATACAND TO BE DIVESTED TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES |
| 6-K | 2020-10-29 | 2020-10-29 | DIRECTORATE CHANGE |
| 6-K | 2020-10-28 | 2020-10-28 | ENHERTU GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF HER2-POSITIVE MET |
| 6-K | 2020-10-28 | 2020-10-28 | FORXIGA CARDIOVASCULAR OUTCOMES BENEFIT APPROVED IN CHINA |
| 6-K | 2020-10-20 | 2020-10-20 | TAGRISSO ADJUVANT LUNG CANCER US PRIORITY REVIEW |
| 6-K | 2020-10-19 | 2020-10-19 | FORXIGA HF RECEIVES POSITIVE CHMP OPINION |
| 6-K | 2020-10-19 | 2020-10-19 | TRIXEO AEROSPHERE RECEIVES POSITIVE CHMP OPINION |
| 6-K | 2020-10-13 | 2020-10-13 | COVID-19 ANTIBODIES ADVANCE AND GET US FUNDING |
| 6-K | 2020-10-02 | 2020-10-02 | FARXIGA GRANTED US BTD IN CHRONIC KIDNEY DISEASE |
| 6-K | 2020-10-01 | 2020-10-01 | TOTAL VOTING RIGHTS |
| 6-K | 2020-09-25 | 2020-09-25 | DIRECTORATE CHANGE |
| 6-K | 2020-09-21 | 2020-09-21 | TAGRISSO REDUCED THE RISK OF DISEASE RECURRENCE IN THE BRAIN BY 82% IN THE ADJUV |
| 6-K | 2020-09-21 | 2020-09-21 | LYNPARZA RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR BRCA-MUTATED METASTATIC |
| 6-K | 2020-09-21 | 2020-09-21 | LYNPARZARECOMMENDED FOR APPROVAL IN EU BY CHMP AS 1ST-LINE MAINTENANCE TREATMENT |
| 6-K | 2020-09-10 | 2020-09-10 | FASENRA MET BOTH CO-PRIMARY ENDPOINTS OF REDUCED NASAL POLYP SIZE AND BLOCKAGE I |
| 6-K | 2020-09-10 | 2020-09-10 | ASTRAZENECA TO LIST US ADR EQUITY AND ALL US DEBT SECURITIES ON NASDAQ |
| 6-K | 2020-09-01 | 2020-09-01 | TOTAL VOTING RIGHTS |
| 6-K | 2020-09-01 | 2020-09-01 | FARXIGA REDUCES CKD PROGRESSION AND RISK OF DEATH |
| 6-K | 2020-09-01 | 2020-09-01 | IMFINZI APPROVED IN EU FOR SMALL CELL LUNG CANCER |
| 6-K | 2020-08-25 | 2020-08-25 | PHASE I CLINICAL TRIAL INITIATED FOR MONOCLONAL ANTIBODY COMBINATION FOR THE PRE |
| 6-K | 2020-08-21 | 2020-08-21 | IMFINZI APPROVED IN JAPAN FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG C |
| 6-K | 2020-08-18 | 2020-08-18 | IMFINZI GRANTED FDA PRIORITY REVIEW FOR LESS-FREQUENT, FIXED-DOSE USE |
| 6-K | 2020-08-06 | 2020-08-06 | FORM 6-K |
| 6-K | 2020-08-04 | 2020-08-04 | ASTRAZENECA PRICES A $3BN BOND ISSUE |
| 6-K | 2020-08-03 | 2020-08-03 | TOTAL VOTING RIGHTS |
| 6-K | 2020-07-30 | 2020-07-30 | TAGRISSO US BTD FOR EGFRM ADJUVANT LUNG CANCER |
| 6-K | 2020-07-30 | 2020-07-30 | AZN: H1 2020 RESULTS |
| 6-K | 2020-07-29 | 2020-07-29 | BOARD COMMITTEE CHANGES |
| 6-K | 2020-07-28 | 2020-07-28 | FARXIGA DAPA-CKD TRIAL MET ALL ENDPOINTS |
| 6-K | 2020-07-27 | 2020-07-27 | ASTRAZENECA ENTERS COLLABORATION IN ONCOLOGY |
| 6-K | 2020-07-27 | 2020-07-27 | CALQUENCE RECEIVES POSITIVE CHMP OPINION FOR CLL |
| 6-K | 2020-07-27 | 2020-07-27 | IMFINZI RECOMMENDED FOR EU APPROVAL IN SCLC |
| 6-K | 2020-07-24 | 2020-07-24 | BREZTRI AEROSPHERE APPROVED IN THE US FOR THE MAINTENANCE TREATMENT OF COPD |
| 6-K | 2020-07-22 | 2020-07-22 | HOLDING(S) IN COMPANY |
| 6-K | 2020-07-22 | 2020-07-22 | HOLDING(S) IN COMPANY |
| 6-K | 2020-07-21 | 2020-07-21 | HOLDING(S) IN COMPANY |
| 6-K | 2020-07-21 | 2020-07-21 | HOLDING(S) IN COMPANY |
| 6-K | 2020-07-20 | 2020-07-20 | COVID-19 VACCINE AZD1222 SHOWED ROBUST IMMUNE RESPONSES IN ALL PARTICIPANTS IN P |
| 6-K | 2020-07-16 | 2020-07-16 | DIRECTOR DECLARATION |
| 6-K | 2020-07-09 | 2020-07-09 | BRILINTA GRANTED US FDA PRIORITY REVIEW FOR STROKE |
| 6-K | 2020-07-08 | 2020-07-08 | LYNPARZA APPROVED IN THE EU FOR BRCA- MUTATED METASTATIC PANCREATIC CANCER |
| 6-K | 2020-07-01 | 2020-07-01 | TOTAL VOTING RIGHTS |
| 6-K | 2020-06-30 | 2020-06-30 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2020-06-30 | 2020-06-30 | SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR NEUROFIBROMATOSIS TYPE |
| 6-K | 2020-06-17 | 2020-06-17 | HOLDING(S) IN COMPANY |
| 6-K | 2020-06-17 | 2020-06-17 | HOLDING(S) IN COMPANY |
| 6-K | 2020-06-15 | 2020-06-15 | ASTRAZENECA TO SUPPLY EUROPE WITH UP TO 400 MILLION DOSES OF OXFORD UNIVERSITY'S |
| 6-K | 2020-06-11 | 2020-06-11 | EMTN PROGRAMME ROUTINE TECHNICAL UPDATE: PUBLICATION OF PROSPECTUS |
| 6-K | 2020-06-01 | 2020-06-01 | LYNPARZA RECOMMENDED FOR APPROVAL IN EU BY CHMP FOR BRCA-MUTATED METASTATIC PANC |
| 6-K | 2020-06-01 | 2020-06-01 | TOTAL VOTING RIGHTS |
| 6-K | 2020-06-01 | 2020-06-01 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2020-06-01 | 2020-06-01 | BRILINTA APPROVED IN THE US TO REDUCE THE RISK OF A FIRST HEART ATTACK OR STROKE |
| 6-K | 2020-05-29 | 2020-05-29 | IMFINZI SHOWED A SUSTAINED OVERALL SURVIVAL BENEFIT IN 1ST-LINE EXTENSIVE-STAGE |
| 6-K | 2020-05-29 | 2020-05-29 | ENHERTUSIGNIFICANTLY IMPROVED TUMOUR RESPONSE RATE AND OVERALL SURVIVAL IN HER2- |
| 6-K | 2020-05-29 | 2020-05-29 | TAGRISSO DEMONSTRATED UNPRECEDENTED DISEASE-FREE SURVIVAL IN THE ADJUVANT TREATM |
| 6-K | 2020-05-26 | 2020-05-26 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2020-05-22 | 2020-05-22 | ENHERTU GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR GASTRIC CANCER |
| 6-K | 2020-05-21 | 2020-05-21 | ASTRAZENECA ADVANCES RESPONSE TO GLOBAL COVID-19 CHALLENGE AS IT RECEIVES FIRST |
| 6-K | 2020-05-20 | 2020-05-20 | LYNPARZA APPROVED IN THE US FOR HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT |
| 6-K | 2020-05-18 | 2020-05-18 | ENHERTU US BREAKTHROUGH STATUS FOR LUNG CANCER |
| 6-K | 2020-05-18 | 2020-05-18 | BEVESPI AEROSPHERE APPROVED IN CHINA FOR COPD |
| 6-K | 2020-05-11 | 2020-05-11 | LYNPARZA APPROVED IN THE US AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F |
| 6-K | 2020-05-11 | 2020-05-11 | ASTRAZENECA RECOVERY OF GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN COM |
| 6-K | 2020-05-11 | 2020-05-11 | ENHERTU GRANTED BREAKTHROUGH THERAPY DESIGNATION IN THE US FOR HER2-POSITIVE MET |
| 6-K | 2020-05-06 | 2020-05-06 | FARXIGA APPROVED IN THE US FOR THE TREATMENT OF HEART FAILURE IN PATIENTS WITH H |
| 6-K | 2020-05-01 | 2020-05-01 | TOTAL VOTING RIGHTS |
| 6-K | 2020-04-29 | 2020-04-29 | AZN: FIRST-QUARTER 2020 RESULTS |
| 6-K | 2020-04-29 | 2020-04-29 | RESULT OF AGM |
| 6-K | 2020-04-24 | 2020-04-24 | LYNPARZA DEMONSTRATED OVERALL SURVIVAL BENEFIT IN PHASE III PROFOUND TRIAL FOR B |
| 6-K | 2020-04-17 | 2020-04-17 | CHANGES TO ARRANGEMENTS FOR ANNUAL GENERAL MEETING |
| 6-K | 2020-04-14 | 2020-04-14 | KOSELUGO (SELUMETINIB) APPROVED IN US FOR PAEDIATRIC PATIENTS WITH NEUROFIBROMAT |
| 6-K | 2020-04-14 | 2020-04-14 | TAGRISSO PHASE III ADAURA TRIAL WILL BE UNBLINDED EARLY AFTER OVERWHELMING EFFIC |
| 6-K | 2020-04-02 | 2020-04-02 | ASTRAZENECA DIVESTMENT OF MOVANTIK TO REDHILL BIOPHARMA COMPLETED |
| 6-K | 2020-04-01 | 2020-04-01 | TOTAL VOTING RIGHTS |
| 6-K | 2020-03-31 | 2020-03-31 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2020-03-30 | 2020-03-30 | FARXIGA PHASE III DAPA-CKD TRIAL WILL BE STOPPED EARLY AFTER OVERWHELMING EFFICA |
| 6-K | 2020-03-30 | 2020-03-30 | IMFINZI APPROVED IN THE US FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER |
| 6-K | 2020-03-26 | 2020-03-26 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2020-03-26 | 2020-03-26 | LOKELMA APPROVED IN JAPAN FOR THE TREATMENT OF HYPERKALAEMIA |
| 6-K | 2020-03-20 | 2020-03-20 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2020-03-19 | 2020-03-19 | LYNPARZA GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR BRCA-MUTATED METASTATIC PA |
| 6-K | 2020-03-17 | 2020-03-17 | IMFINZI CONFIRMED A SUSTAINED OVERALL SURVIVAL BENEFIT IN FINAL ANALYSIS OF THE |
| 6-K | 2020-03-12 | 2020-03-12 | 6-K |
| 6-K | 2020-03-12 | 2020-03-12 | NOTICE OF AGM |
| 6-K | 2020-03-12 | 2020-03-12 | UPDATE ON PHASE III GY004 TRIAL FOR CEDIRANIB ADDED TO LYNPARZA IN PLATINUM-SENS |
| 6-K | 2020-03-10 | 2020-03-10 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2020-03-06 | 2020-03-06 | UPDATE ON PHASE III DANUBE TRIAL FOR IMFINZI AND TREMELIMUMAB IN UNRESECTABLE, S |
| 6-K | 2020-03-04 | 2020-03-04 | FILING OF FORM 20-F WITH SEC |
| 20-F | 2019-12-31 | 2020-03-03 | 20-F |
| 6-K | 2020-03-03 | 2020-03-03 | ANNUAL FINANCIAL REPORT |
| 6-K | 2020-03-02 | 2020-03-02 | TOTAL VOTING RIGHTS |
| 6-K | 2020-03-02 | 2020-03-02 | ASTRAZENECA COMPLETES DIVESTMENT AGREEMENT WITH ATNAHS PHARMA FOR ESTABLISHED HY |
| 6-K | 2020-02-27 | 2020-02-27 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2020-02-25 | 2020-02-25 | ASTRAZENECA DIVESTS GLOBAL RIGHTS TO MOVANTIK |
| 6-K | 2020-02-19 | 2020-02-19 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2020-02-14 | 2020-02-14 | AZN: FULL-YEAR AND Q4 2019 RESULTS |
| 6-K | 2020-02-03 | 2020-02-03 | TOTAL VOTING RIGHTS |
| 6-K | 2020-01-27 | 2020-01-27 | ASTRAZENECA DIVESTS RIGHTS TO ESTABLISHED HYPERTENSION MEDICINES |
| 6-K | 2020-01-27 | 2020-01-27 | PHASE II DESTINY-GASTRIC01 TRIAL OF ENHERTU VERSUS CHEMOTHERAPY MET PRIMARY ENDP |
| 6-K | 2020-01-27 | 2020-01-27 | ASTRAZENECA TO RECOVER THE GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN |
| 6-K | 2020-01-27 | 2020-01-27 | BRILINTA MET PRIMARY ENDPOINT IN PHASE III THALES TRIAL IN STROKE |
| 6-K | 2020-01-20 | 2020-01-21 | LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR HRR-MUTATED |
| 6-K | 2020-01-20 | 2020-01-21 | IMFINZI AND TREMELIMUMAB GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR LIVER CAN |
| 6-K | 2020-01-13 | 2020-01-13 | LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR 1ST-LINE MA |
| 6-K | 2020-01-13 | 2020-01-13 | UPDATE ON PHASE III STRENGTH TRIAL FOR EPANOVA IN MIXED DYSLIPIDAEMIA |
| 6-K | 2020-01-06 | 2020-01-06 | LOKELMA APPROVED IN CHINA FOR THE TREATMENT OF ADULT PATIENTS WITH HYPERKALAEMIA |
| 6-K | 2020-01-06 | 2020-01-06 | FARXIGA GRANTED FDA PRIORITY REVIEW FOR PATIENTS WITH HEART FAILURE WITH REDUCED |
| 6-K | 2020-01-02 | 2020-01-02 | TOTAL VOTING RIGHTS |
| 6-K | 2019-12-30 | 2019-12-30 | LYNPARZAAPPROVED IN THE US AS A 1ST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA- |
| 6-K | 2019-12-23 | 2019-12-23 | ENHERTU (TRASTUZUMAB DERUXTECAN) APPROVED IN THE US FOR HER2-POSITIVE UNRESECTAB |
| 6-K | 2019-12-23 | 2019-12-23 | ASTRAZENECA'S TRIPLE-COMBINATION THERAPY APPROVED IN CHINA FOR PATIENTS WITH COP |
| 6-K | 2019-12-20 | 2019-12-20 | ASTRAZENECA DIVESTS RIGHTS TO ARIMIDEX AND CASODEX IN EUROPE AND CERTAIN ADDITIO |
| 6-K | 2019-12-17 | 2019-12-17 | FDA PANEL BACKS LYNPARZA USE FOR PANCREATIC CANCER |
| 6-K | 2019-12-16 | 2019-12-16 | SEROQUEL RIGHTS AGREEMENT COMPLETE: EUROPE, RUSSIA |
| 6-K | 2019-12-12 | 2019-12-12 | IMFINZI APPROVED IN CHINA FOR THE TREATMENT OF UNRESECTABLE, STAGE III NON-SMALL |
| 6-K | 2019-12-11 | 2019-12-11 | TRASTUZUMAB DERUXTECAN ACHIEVED A TUMOUR RESPONSE RATE OF 60.9% IN PIVOTAL PHASE |
| 6-K | 2019-12-05 | 2019-12-05 | LYNPARZA APPROVED IN CHINA AS A 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADV |
| 6-K | 2019-12-03 | 2019-12-03 | ASTRAZENECA DIVESTS RIGHTS TO SEROQUEL AND SEROQUEL XR IN THE US AND CANADA |
| 6-K | 2019-12-02 | 2019-12-02 | TOTAL VOTING RIGHTS |
| 6-K | 2019-12-02 | 2019-12-02 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2019-11-29 | 2019-11-29 | IMFINZI GRANTED FDA PRIORITY REVIEW FOR THE TREATMENT OF PATIENTS WITH EXTENSIVE |
| 6-K | 2019-11-21 | 2019-11-21 | CALQUENCE APPROVED IN THE US FOR ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEM |
| 6-K | 2019-11-15 | 2019-11-15 | QTRILMET APPROVED IN THE EU FOR TREATMENT OF T2D |
| 6-K | 2019-11-14 | 2019-11-14 | FDA ACCEPTS REGULATORY SUBMISSION FOR SELUMETINIB |
| 6-K | 2019-11-12 | 2019-11-12 | ROXADUSTAT PHASE III PROGRAMME POOLED ANALYSES SHOWED POSITIVE EFFICACY AND NO I |
| 6-K | 2019-11-12 | 2019-11-12 | ANIFROLUMAB DEMONSTRATED SUPERIORITY ACROSS MULTIPLE EFFICACY ENDPOINTS IN PATIE |
| 6-K | 2019-11-08 | 2019-11-08 | ROXADUSTAT SIGNIFICANTLY INCREASED HAEMOGLOBIN LEVELS FOR CHRONIC KIDNEY DISEASE |
| 6-K | 2019-11-06 | 2019-11-06 | CALQUENCE DATA TO SHOW IMPROVED PROGRESSION-FREE SURVIVAL IN PHASE III FRONT-LIN |
| 6-K | 2019-11-01 | 2019-11-01 | TOTAL VOTING RIGHTS |
| 6-K | 2019-10-30 | 2019-10-30 | ASTRAZENECA DIVESTS RIGHTS TO SEROQUEL AND SEROQUEL XR IN EUROPE AND RUSSIA |
| 6-K | 2019-10-28 | 2019-10-28 | IMFINZI AND IMFINZI PLUS TREMELIMUMAB DELAYED |
| 6-K | 2019-10-24 | 2019-10-24 | ASTRAZENECA YEAR-TO-DATE AND Q3 2019 RESULTS |
| 6-K | 2019-10-21 | 2019-10-21 | FARXIGA APPROVED IN THE US TO REDUCE THE RISK OF HOSPITALISATION FOR HEART FAILU |
| 6-K | 2019-10-17 | 2019-10-17 | TRASTUZUMAB DERUXTECAN GRANTED FDA PRIORITY REVIEW FOR TREATMENT OF PATIENTS WIT |
| 6-K | 2019-10-04 | 2019-10-04 | FASENRA APPROVED IN THE US FOR SELF-ADMINISTRATION |
| 6-K | 2019-10-04 | 2019-10-04 | HOLDING(S) IN COMPANY |
| 6-K | 2019-10-04 | 2019-10-04 | HOLDING(S) IN COMPANY |
| 6-K | 2019-10-03 | 2019-10-03 | DIRECTOR DECLARATION |
| 6-K | 2019-10-01 | 2019-10-01 | TOTAL VOTING RIGHTS |
| 6-K | 2019-10-01 | 2019-10-01 | UPDATE ON US REGULATORY REVIEW OF PT010 IN COPD |
| 6-K | 2019-10-01 | 2019-10-01 | ASTRAZENECA DIVESTS RIGHTS FOR LOSEC TO CHEPLAPHAR |
| 6-K | 2019-09-30 | 2019-09-30 | TAGRISSO IS THE ONLY 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CELL LUNG CAN |
| 6-K | 2019-09-30 | 2019-09-30 | LYNPARZA MORE THAN DOUBLED THE TIME WITHOUT RADIOGRAPHIC DISEASE PROGRESSION IN |
| 6-K | 2019-09-30 | 2019-09-30 | LYNPARZA IMPROVED THE TIME WOMEN LIVED WITHOUT DISEASE PROGRESSION TO 22 MONTHS |
| 6-K | 2019-09-23 | 2019-09-23 | QTRILMET RECOMMENDED FOR APPROVAL IN EU BY CHMP |
| 6-K | 2019-09-18 | 2019-09-18 | ASTRAZENECA AMENDS COLLABORATION WITH IRONWOOD FOR LINZESS IN CHINA |
| 6-K | 2019-09-09 | 2019-09-09 | IMFINZI IS FIRST IMMUNOTHERAPY TO SHOW BOTH SIGNIFICANT SURVIVAL BENEFIT AND IMP |
| 6-K | 2019-09-04 | 2019-09-04 | TAGRISSO APPROVED IN CHINA AS A 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CE |
| 6-K | 2019-09-03 | 2019-09-03 | TOTAL VOTING RIGHTS |
| 6-K | 2019-09-03 | 2019-09-03 | DETAILED RESULTS FROM PHASE III DAPA-HF TRIAL SHOWED FARXIGA SIGNIFICANTLY REDUC |
| 6-K | 2019-09-03 | 2019-09-03 | BRILINTA REDUCED THE RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY ART |
| 6-K | 2019-08-29 | 2019-08-29 | ANIFROLUMAB PHASE III TRIAL MEETS PRIMARY ENDPOINT IN SYSTEMIC LUPUS ERYTHEMATOS |
| 6-K | 2019-08-28 | 2019-08-28 | FASENRA GRANTED US ORPHAN DRUG DESIGNATION FOR EOSINOPHILIC OESOPHAGITIS |
| 6-K | 2019-08-28 | 2019-08-28 | BREZTRI AEROSPHERE PHASE III ETHOS TRIAL MET ITS PRIMARY ENDPOINT IN CHRONIC OBS |
| 6-K | 2019-08-22 | 2019-08-22 | ROXADUSTAT APPROVED IN CHINA FOR THE TREATMENT OF ANAEMIA IN NON-DIALYSIS-DEPEND |
| 6-K | 2019-08-22 | 2019-08-22 | ASTRAZENECA AGREES TO BUY US FDA PRIORITY REVIEW |
| 6-K | 2019-08-21 | 2019-08-21 | UPDATE ON THE PHASE III NEPTUNE TRIAL |
| 6-K | 2019-08-20 | 2019-08-20 | FARXIGA MET PRIMARY ENDPOINT IN LANDMARK PHASE III |
| 6-K | 2019-08-19 | 2019-08-19 | DIRECTORATE CHANGE |
| 6-K | 2019-08-14 | 2019-08-14 | LYNPARZA PHASE III PAOLA-1 TRIAL MET PRIMARY ENDPOINT |
| 6-K | 2019-08-14 | 2019-08-14 | CALQUENCE GRANTED US BREAKTHROUGH THERAPY DESIGNATION |
| 6-K | 2019-08-09 | 2019-08-09 | TAGRISSO SIGNIFICANTLY IMPROVES OVERALL SURVIVAL |
| 6-K | 2019-08-07 | 2019-08-07 | LYNPARZA PHASE III PROFOUND TRIAL IN HRR* |
| 6-K | 2019-08-05 | 2019-08-05 | FORXIGA LABEL UPDATED IN THE EU IN TYPE-2 DIABETES |
| 6-K | 2019-08-01 | 2019-08-01 | TOTAL VOTING RIGHTS |
| 6-K | 2019-06-30 | 2019-07-25 | 6-K |
| 6-K | 2019-07-15 | 2019-07-15 | UPDATE ON US REGULATORY DECISION FOR FARXIGA |
| 6-K | 2019-07-12 | 2019-07-12 | IMFINZI GRANTED US ORPHAN DRUG DESIGNATION FOR SMALL CELL LUNG CANCER |
| 6-K | 2019-07-01 | 2019-07-01 | FASENRA RECEIVES POSITIVE EU CHMP OPINION FOR SELF |
| 6-K | 2019-07-01 | 2019-07-01 | FORXIGA RECEIVES POSITIVE EU CHMP OPINION FOR |
| 6-K | 2019-07-01 | 2019-07-01 | TOTAL VOTING RIGHTS |
| 6-K | 2019-06-27 | 2019-06-27 | IMFINZI IMPROVES OVERALL SURVIVAL AT INTERIM |
| 6-K | 2019-06-19 | 2019-06-19 | LYNPARZA APPROVED IN JAPAN FOR 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADVA |
| 6-K | 2019-06-19 | 2019-06-19 | BEVESPI AEROSPHERE APPROVED BY THE JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFA |
| 6-K | 2019-06-19 | 2019-06-19 | BREZTRI AEROSPHERE (PT010) APPROVED IN JAPAN FOR PATIENTS WITH CHRONIC OBSTRUCTI |
| 6-K | 2019-06-18 | 2019-06-18 | LYNPARZA APPROVED IN THE EU FOR 1ST-LINE |
| 6-K | 2019-06-17 | 2019-06-17 | CALQUENCE SIGNIFICANTLY PROLONGED THE TIME PATIENT |
| 6-K | 2019-06-12 | 2019-06-12 | PUBLICATION OF A PROSPECTUS |
| 6-K | 2019-06-06 | 2019-06-06 | CALQUENCE PHASE III ELEVATE-TN TRIAL MET PRIMARY |
| 6-K | 2019-06-03 | 2019-06-03 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2019-06-03 | 2019-06-03 | TOTAL VOTING RIGHTS |
| 6-K | 2019-06-03 | 2019-06-03 | LYNPARZA NEARLY DOUBLED THE TIME PATIENTS LIVED WITHOUT DISEASE PROGRESSION FROM |
| 6-K | 2019-05-10 | 2019-05-10 | POOLED ANALYSES OF THE ROXADUSTAT GLOBAL PHASE III |
| 6-K | 2019-05-08 | 2019-05-08 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2019-05-08 | 2019-05-08 | DIRECTOR DECLARATION |
| 6-K | 2019-05-08 | 2019-05-08 | TRASTUZUMAB DERUXTECAN DEMONSTRATED CLINICALLY |
| 6-K | 2019-05-07 | 2019-05-07 | CALQUENCE PHIII ASCEND TRIAL MET PRIMARY ENDPOINT |
| 6-K | 2019-05-03 | 2019-05-03 | QTERNMET XR APPROVED IN THE US FOR TYPE-2 DIABETES |
| 6-K | 2019-05-01 | 2019-05-01 | TOTAL VOTING RIGHTS |
| 6-K | 2019-05-01 | 2019-05-01 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2019-04-29 | 2019-04-29 | LYNPARZA RECEIVES POSITIVE EU CHMP OPINION FOR 1ST |
| 6-K | 2019-04-26 | 2019-04-26 | AZN: Q1 2019 RESULTS |
| 6-K | 2019-04-26 | 2019-04-26 | RESULT OF AGM |